Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting

SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) — Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced that it will present positive data from its herpes simplex virus-1 keratitis program, EBT-104, as well as an overview of a next-generation AAV delivery vector, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks